Waldenstrom macroglobulinemia - Development of diagnostic criteria and identification of prognostic factors

被引:94
|
作者
Owen, RG
Barrans, SL
Richards, SJ
O'Connor, SJM
Child, JA
Parapia, LA
Morgan, GJ
Jack, AS
机构
[1] Gen Infirm, HMDS Lab, Dept Hematol, Leeds LS1 3EX, W Yorkshire, England
[2] Bradford Royal Infirm, Dept Hematol, Bradford BD9 6RJ, W Yorkshire, England
关键词
Waldenstrom macroglobulinemia; immunophenotype; prognostic factors;
D O I
10.1309/4LCN-JMPG-5U71-UWQB
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
To establish whether a combination of morphologic and immunophenotypic criteria could be developed to more precisely define Waldenstrom macroglobulinemia (WM) and prognostic factors, we retrospectively assessed the clinical and laboratory, features of 111 cases of WM. Bone marrow infiltration by small lymphocytes was documented in each case; and diffuse, interstitial, nodular and paratrabecular patterns of infiltration were documented in 58%, 32%, 6%, and 4% of cases, respectively. Ninety percent were characterized by a surface immunoglobulin-positive, CDl9+CD20+CD5-CDI0-CD23- immunophenotype. The median overall survival from diagnosis was 60 months; univariate analysis revealed the following adverse prognostic factors: older than 60 years, performance status more than 1. platelet count less than 100 x 10(3)/muL (< 100 x 10(9)/L), pancytopenia, and diffuse bone marrow infiltration. Associated median survival it-as 40, 38, 46, 28, and 59 months, respectively. Multivariate analysis revealed age, performance status, and platelet count as prognostically significant, but stratification of patients according to the International Prognostic Index had limited value. We suggest defining WM by the following criteria: IgM monoclonal gammopathy; bone marrow infiltration by small lymphocytes, plasmacytoid cells, and plasma cells in a diffuse, interstitial, or nodular pattern; and a surface immunoglobulin-positive, CD19+CD20+CD5-CD10-CD23- immunophenotype.
引用
收藏
页码:420 / 428
页数:9
相关论文
共 50 条
  • [11] IgM MGUS and asymptomatic Waldenstrom's macroglobulinemia: Prognostic factors and evolution
    Morra, E.
    Cesana, C.
    Barbarano, L.
    Varettoni, M.
    Bemuzzi, P.
    Tedeschi, A.
    Cavanna, I.
    Lazzarino, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 82 - 83
  • [12] Diagnostic Challenges of Amyloidosis in Waldenstrom Macroglobulinemia
    Palladini, Giovanni
    Merlini, Giampaolo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (02): : 244 - 246
  • [13] Waldenstrom Macroglobulinemia of the orbit: A diagnostic challenge
    Adiga, Sushant
    Mehta, Aditi
    Singh, Usha
    Singh, Charanpreet
    Sharma, Rintu
    Banerjee, Nirmalya
    Lad, Deepesh
    Rastogi, Pulkit
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2022, 32 (01) : NP246 - NP250
  • [14] The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia
    Chin, Collin K.
    Leslie, Connull
    Grove, Carolyn S.
    Van Vliet, Chris
    Cheah, Chan Yoon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (10)
  • [15] Diagnostic and prognostic use of FDG-PET scans in Waldenstrom's macroglobulinemia
    Harris, B.
    Leleu, X.
    Leduc, R.
    Yarar, D.
    Sam, A.
    Rourke, M.
    Chuma, S.
    Roccaro, A.
    Ghobrial, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [16] Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia
    Dimopoulos, MA
    Hamilos, G
    Zervas, K
    Symeonidis, A
    Kouvatseas, G
    Roussou, P
    Gika, D
    Karmiris, T
    Bourantas, K
    Zomas, A
    Mitsouli, C
    Xilouri, I
    Vervessou, E
    Matsis, K
    Anagnostopoulos, N
    Economopoulos, T
    ANNALS OF ONCOLOGY, 2003, 14 (08) : 1299 - 1305
  • [17] Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia:: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
    Kyle, RA
    Treon, SP
    Alexanian, R
    Barlogie, B
    Björkholm, M
    Dhodapkar, M
    Lister, TA
    Merlini, G
    Morel, P
    Stone, M
    Branagan, AR
    Leblond, W
    SEMINARS IN ONCOLOGY, 2003, 30 (02) : 116 - 120
  • [18] Treatment of Waldenstrom's macroglobulinemia with rituximab: Prognostic factors for response and progression.
    Dimopoulos, MA
    Zervas, K
    Zomas, A
    Anagnostopoulos, A
    Kyrtsonis, MC
    Anagnostopoulos, N
    Pangalis, G
    Weber, D
    BLOOD, 2003, 102 (11) : 448A - 448A
  • [19] Prognostic factors and primary treatment for Waldenstrom macroglobulinemia - a Swedish Lymphoma Registry study
    Brandefors, Lena
    Melin, Beatrice
    Lindh, Jack
    Lundqvist, Kristina
    Kimby, Eva
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (04) : 564 - 577
  • [20] Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.
    Dimopolous, MA
    Hamilos, G
    Symeonidis, A
    Kouvatseas, G
    Zervas, K
    Panayiotidis, P
    Gika, D
    Karmiris, T
    Bouradas, K
    Grigoraki, V
    Zomas, A
    Anagnostopoulos, N
    Economopoulos, T
    BLOOD, 2002, 100 (11) : 604A - 604A